 |
Why Jeil pharma for CMO & CDMO !!!
 From API to FinishedJeil pharma is capable of producing from Active Pharmaceutical Ingredients to Finished Products at the same site, eventually enabling to make a more attractive offer to potential customers.
R&D Capabilities : Formulation DevelopmentThrough constant investment on R&D center, Jeil pharma has accumulated technology and know-how over 20 years in APIs and finished products, now Jeil pharma produces not only generics but also improved combination drugs and patches.
Dedicated FacilitiesJeil pharma’s 5 dedicated facilities are able to meet variety needs of many customers’ and approved to comply with the GMP of PMDA(Japan). |
| 1) The new plant for oral dosage | 2) Cytotoxic Anti-Cancer plant (API and oral dosage) | |
 |
 |
|
| - Newly built in 2017 and PICS GMP approved - Production capacity : 1.5 billion units/year - Available oral dosage forms: tablets, capsules, granules |
- Built in 2012 and GMP Approved. - Available oral dosage forms: tablets, capsules, granules |
| Product | In production | Remarks |
| General API | Epinastine, Rosuvastatin etc | |
| Carba-penem antibiotics | Meropenem, Imipenem | Finished products(inj) |
| Oncology | Irinotecan, Azacitidine | Finished products(oral) |
| Cephalosporin (Non-sterile) | Cefditore Pivoxil, Cefcapen Pivoxil, Cefdinir, Cefpodoxime axetil | |
| Cephalosporin (Sterile) | Cefmetazole sodium, Flomoxef |
